Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound

US9062047B2 · kind B2 · utility

Assignee

• Verona Pharma PLC · GB

Inventors

• Michael J. A. Walker · Vancouver, CA
• Bertrand M. C. Plouvier · Vancouver, CA
• Julian Scott Northen · Sunderland, GB
• Philippe Fernandes · Turnhout, BE

Key dates

• Filing date: Aug 9, 2011
• Grant date: Jun 23, 2015
• Expiry date: Aug 21, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The current invention is directed towards a polymorph of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, in the form of a crystalline solid consisting of greater than 99% by weight of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, at least 95% in the polymorphic form of a thermodynamically stable polymorph (I) of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, wherein said polymorph is determined by single crystal X-ray structural analysis and X-ray powder diffraction pattern.